<DOC>
	<DOCNO>NCT02155647</DOCNO>
	<brief_summary>This multicenter , international , single-arm , open-label , Phase 2 trial evaluate efficacy safety avelumab subject metastatic Merkel cell carcinoma ( MCC ) .</brief_summary>
	<brief_title>Avelumab Subjects With Merkel Cell Carcinoma ( JAVELIN Merkel 200 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Merkel Cell</mesh_term>
	<criteria>Signed write informed consent Age 18 year Histologically proven MCC Subjects must receive least 1 line chemotherapy metastatic MCC must progress recent line chemotherapy For Part B Subjects must receive prior systemic treatment metastatic MCC . Prior chemotherapy treatment adjuvant setting ( clinically detectable disease ; metastatic disease ) allowable end treatment occur least 6 month prior study start ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Disease must measurable least 1 unidimensional measurable lesion RECIST Version 1.1 ( include skin lesion ) Adequate hematological , hepatic renal function ( renal function consider adequate per protocol definition ) Highly effective contraception male female subject , risk conception exist Fresh Biopsy Archival Tumor Tissue Estimated life expectancy 12 week Participation another interventional clinical trial within past 30 day ( participation observational study permit ) Concurrent treatment non permit drug Prior therapy antibody/drug target Tcell coregulatory protein ( immune checkpoint ) antiprogrammed death 1 ( PD1 ) , antiPDL1 , anticytotoxic Tlymphocyte antigen4 ( CTLA4 ) antibody ; Part B , Investigator must consult Medical Monitor consider coregulatory target 41BB Concurrent anticancer treatment ( example , cytoreductive therapy , radiotherapy [ exception palliative bonedirected radiotherapy , radiotherapy administer nontarget superficial lesion ] , immune therapy , cytokine therapy except erythropoietin ) . Radiotherapy administer superficial lesion allow lesion consider target lesion efficacy evaluation may influence efficacy evaluation investigational agent Major surgery reason , except diagnostic biopsy , within 4 week and/or subject fully recover surgery within 4 week Concurrent systemic therapy steroid immunosuppressive agent , use investigational drug within 28 day start trial treatment . Shortterm administration systemic steroid ( , allergic reaction management immunerelated adverse event [ irAE ] ) study allow . Note : Subjects receive bisphosphonate denosumab eligible Subjects active central nervous system ( CNS ) metastases exclude . Subjects history treat CNS metastasis ( surgery radiation therapy ) eligible unless fully recover treatment , demonstrate progression least 2 month , require continued steroid therapy Previous malignant disease ( MCC ) within last 5 year exception basal squamous cell carcinoma skin Part A cervical carcinoma situ Part B carcinoma situ ( skin , bladder , cervical , colorectal , breast low grade prostatic intraepithelial neoplasia Grade 1 prostate cancer ) Prior organ transplantation , include allogeneic stemcell transplantation Part A : Known history test positive HIV know acquire immunodeficiency syndrome ( AIDS ) positive test hepatitis B virus hepatitis C virus indicate acute chronic infection . For Part B , know history test positive HIV know AIDS consultation Medical Monitor HBV HCV infection screening ( positive HBV surface antigen HCV RNA anti HCV antibody screen test positive ) . Active history autoimmune disease ( except subject vitiligo ) immunodeficiency require treatment systemic immunosuppressive drug Known severe hypersensitivity reaction monoclonal antibody ( Grade great equal ( &gt; = ) 3 NCI CTCAE v 4.0 ) , history anaphylaxis , uncontrolled asthma ( , 3 feature partially control asthma ) Persisting toxicity relate prior therapy Grade &gt; 1 NCICTCAE v 4.0 ; however , sensory neuropathy Grade &lt; = 2 acceptable 14 . Pregnancy lactation Known alcohol drug abuse Clinically significant ( , active ) cardiovascular disease : cerebral vascular accident / stroke ( &lt; 6 month prior enrollment ) , myocardial infarction ( &lt; 6 month prior enrollment ) , unstable angina , congestive heart failure ( New York Heart Association Classification Class &gt; = II ) , serious cardiac arrhythmia require medication All significant disease ( example , inflammatory bowel disease ) , , opinion Investigator , might impair subject 's tolerance trial treatment Any psychiatric condition would prohibit understanding rendering informed consent Legal incapacity limit legal capacity Non oncology vaccine therapy prevention infectious disease ( example , seasonal flu vaccine , human papilloma virus vaccine ) within 4 week trial drug administration . Vaccination trial also prohibit except administration inactivate vaccine ( example , inactivate seasonal influenza vaccine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Carcinoma , Merkel Cell</keyword>
	<keyword>MSB0010718C</keyword>
	<keyword>avelumab</keyword>
	<keyword>anti PD-L1</keyword>
	<keyword>JAVELIN Merkel 200</keyword>
</DOC>